Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Core Viewpoint - Agios Pharmaceuticals is pursuing U.S. accelerated approval for mitapivat, an oral pyruvate kinase activator, for the treatment of sickle cell disease after a pre-supplemental New Drug Application meeting with the FDA [1][2] Group 1: FDA Engagement and Approval Process - The pre-sNDA meeting aimed to present data from the mitapivat RISE UP clinical program, including Phase 2 and Phase 3 trials, leading to the FDA's recommendation for a confirmatory clinical trial to support accelerated approval [2][3] - Agios has submitted a proposal for the required confirmatory clinical trial, which includes a primary endpoint different from those in the RISE UP program, based on data analysis and discussions with the FDA [3][4] Group 2: Clinical Trial Details - The global RISE UP Phase 3 trial evaluated the efficacy and safety of mitapivat in sickle cell disease patients aged 16 years or older, involving 207 participants randomized to receive either mitapivat or placebo [7] - The double-blind phase included primary endpoints of hemoglobin response and annualized rate of sickle cell pain crises, along with key secondary endpoints measuring various clinical outcomes [9] Group 3: Efficacy and Safety Results - Mitapivat showed a statistically significant improvement in the primary endpoint of hemoglobin response, defined as a ≥1.0 g/dL increase from baseline in average hemoglobin concentration from Week 24 through Week 52 [10] - Patients receiving mitapivat who achieved the hemoglobin response also experienced clinically meaningful benefits, including reductions in pain crises and related hospital visits, with a favorable safety profile consistent with prior trials [11] Group 4: Sickle Cell Disease Overview - Sickle cell disease is a rare inherited blood disorder characterized by abnormal hemoglobin production, leading to rigid, sickle-shaped red blood cells that cause severe complications and increased healthcare needs [5] - The disease imposes a significant burden on patients and families, resulting in chronic hemolytic anemia and life-threatening complications affecting multiple organ systems [5] Group 5: Mitapivat Mechanism of Action - Mitapivat is designed to enhance energy production in red blood cells, potentially improving their health by increasing ATP levels and lowering 2,3-diphosphoglycerate levels, which are elevated in sickle cell disease [6]